Healthcare-associated pneumonia: Approach to management

Clinics in Chest Medicine

Volumn 32, Issue 3, 2011, Pages 507-515

  Labelle, Andrew ^a   Kollef, Marin H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotic therapy; Community acquired; Healthcare associated; Pneumonia; Risk factors

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFEPIME; IMIPENEM; LINEZOLID; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; BACTERIUM CULTURE; COMMUNITY ACQUIRED PNEUMONIA; EARLY INTERVENTION; ENTEROBACTERIACEAE; ESCHERICHIA COLI; HAEMOPHILUS; HEALTH CARE ASSOCIATED PNEUMONIA; HEMODIALYSIS PATIENT; HOSPITAL CARE; HOSPITALIZATION; HUMAN; IMMUNE DEFICIENCY; INDIVIDUALIZATION; INFECTIOUS PNEUMONIA; KLEBSIELLA; LONG TERM CARE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NURSING HOME; PATIENT CARE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PSEUDOMONAS AERUGINOSA; REVIEW; RISK ASSESSMENT; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT DURATION;

COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; PNEUMONIA, BACTERIAL; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 80051868652     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2011.05.003     Document Type: Review

References (67)

1. Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416. American Thoracic Society.
2. McDonald J.R., Friedman N.D., Stout J.E., et al. Risk factors for ineffective therapy in patients with bloodstream infections. Arch Intern Med 2005, 165:308-313.
3. Kollef M.H., Shorr A., Tabak Y.P., et al. Epidemiology and outcomes of health care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005, 128:3854-3862.
4. Micek S.T., Kollef K.E., Reichley R.M., et al. Health care-associated pneumonia and community-acquired pneumonia: a single center experience. Antimicrob Agents Chemother 2007, 51:3568-3573.
5. Amin A., Kollef M.H. Health care-associated pneumonia. Hosp Pract 2010, 38:1-12.
6. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44:S27-S72.
7. Friedman N.B., Kaye K.S., Stout J.E., et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002, 137:791-797.
8. Carratalà J., Mykietiuk A., Fernández-Sabé N., et al. Healthcare-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. Arch Intern Med 2007, 167:1393-1399.
9. Venditti M., Falcone M., Corrao S., et al. Study Group of the Italian Society of Internal Medicine. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. Ann Intern Med 2009, 150:19-26.
10. Shindo Y., Sato S., Maruyama E., et al. Healthcare-associated pneumonia among hospitalized patients in a Japanese community hospital. Chest 2009, 135:633-640.
11. Cecere L.M., Rubenfeld G.D., Park D.R., et al. Long-term survival after hospitalization for community-acquired and healthcare-associated pneumonia. Respiration 2010, 79:128-136.
12. Labelle A.J., Arnold H., Reichley R.M., et al. A comparison of culture-positive and culture-negative healthcare-associated pneumonia. Chest 2010, 137:1130-1137.
13. Schreiber M.P., Chan C.M., Shorr A.F. Resistant pathogens in non-nosocomial pneumonia and respiratory failure: is it time to refine the definition of healthcare-associated pneumonia?. Chest 2010, 137:1283-1288.
14. Falcone M., Venditti M., Corrao, et al. Role of multidrug-resistant pathogens in health care-associated pneumonia. Lancet Infect Dis 2001, 11:11-12.
15. Shorr A.F., Zilberberg M.D., Micek S.T., et al. Prediction of infection due to antibiotic-resistant bacteria by select risk factors for healthcare-associated pneumonia. Arch Intern Med 2008, 168:2205-2210.
16. Rello J., Luján M., Gallego M., et al. Why mortality is increased in Healthcare-associated Pneumonia: lessons from pneumococcal bacteremic pneumonia. Chest 2010, 137:1138-1144.
17. Webster D., Chui L., Tyrrell G.J., et al. Healthcare-associated Staphylococcus aureus pneumonia. Can J Infect Dis Med Microbiol 2007, 18:181-188.
18. Ewig S., Welte T., Chastre J., et al. Rethinking the concepts of community-acquired and health-care-associated pneumonia. Lancet Infect Dis 2010, 10:279-287.
19. Huang S.S., Datta R., Platt R. Risk of acquiring antibiotic-resistant bacteria from prior room occupants. Arch Intern Med 2006, 166:1945-1951.
20. Friedmann R., Raveh D., Zartzer E., et al. Prospective evaluation of colonization with extended-spectrum beta-lactamase (ESBL)-producing enterobacteriaceae among patients at hospital admission and of subsequent colonization with ESBL-producing enterobacteriaceae among patients during hospitalization. Infect Control Hosp Epidemiol 2009, 30:534-542.
21. Scanvic A., Denic L., Gaillon S., et al. Duration of colonization by methicillin-resistant Staphylococcus aureus after hospital discharge and risk factors for prolonged carriage. Clin Infect Dis 2001, 32:1393-1398.
22. Marschall J., Mühlemann K. Duration of methicillin-resistant Staphylococcus aureus carriage, according to risk factors for acquisition. Infect Control Hosp Epidemiol 2006, 27:1206-1212.
23. Zahar J.R., Lanternier F., Mechai F., et al. Duration of colonisation by Enterobacteriaceae producing extended-spectrum beta-lactamase and risk factors for persistent faecal carriage. J Hosp Infect 2010, 75:76-78.
24. Niederman M.S., Mandell La, Anzueto A., et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001, 163:1730-1754. American Thoracic Society.
25. Bradley S.F., Terpenning M.S., Ramsey M.A., et al. Methicillin-resistant Staphylococcus aureus: colonization and infection in a long-term-care facility. Ann Intern Med 1991, 115:417-422.
26. Muder R.R., Brennen C., Wagener M.M., et al. Methicillin-resistant staphylococcal colonization and infection in a long-term care facility. Ann Intern Med 1991, 114:107-112.
27. Pop-Vicas A., Mitchell S.L., Kandel R., et al. Multidrug-resistant gram-negative bacteria in a long-term care facility: prevalence and risk factors. J Am Geriatr Soc 2008, 56:1276-1280.
28. El-Solh A.A., Sikka P., Ramadan F., et al. Etiology of severe pneumonia in the very elderly. Am J Respir Crit Care Med 2001, 163:645-651.
29. Kothe H., Bauer T., Marre R., et al. Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. Eur Respir J 2008, 32:139-146.
30. El Solh A.A., Niederman N.S., Drinka P. Management of pneumonia in the nursing home. Chest 2010, 138:1480-1485.
31. El Solh A.A., Pietrantoni C., Bhat A., et al. Indicators of potentially drug-resistant bacteria in severe nursing home-acquired pneumonia. Clin Infect Dis 2004, 39:474-480.
32. El Solh A.A., Akinnusi M.E., Alfarah Z., et al. Effect of antibiotic guidelines of hospitalized patients with nursing home-acquired pneumonia. J Am Geriatr Soc 2009, 57:1030-1035.
33. Mermel L.A., Eells S.J., Acharya M.K., et al. Quantitative analysis and molecular fingerprinting of methicillin-resistant Staphylococcus aureus nasal colonization in different patient populations: a prospective, multicenter study. Infect Control Hosp Epidemiol 2010, 31:592-597.
34. Berman S.J., Johnson E.W., Nakatsu C., et al. Burden of infection in patients with end-stage renal disease requiring long-term dialysis. Clin Infect Dis 2004, 39:1747-1753.
35. Rañó A., Agustí C., Jimenez P., et al. Pulmonary infiltrates in non-HIV immunocompromised patients: a diagnostic approach using noninvasive and bronchoscopic procedures. Thorax 2001, 56:379-387.
36. Ibrahim E.H., Sherman G., Ward S., et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000, 118:146-155.
37. Kollef M.H. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000, 31:S131-S138.
38. Kollef M.H., Sherman G., Ward S., et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 2000, 115:462-474.
39. Micek S.T., Loyd A.E., Ritchie D.J., et al. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimocrob Agents Chemother 2005, 49:1306-1311.
40. Schramm G.E., Johnson J.A., Doherty J.A., et al. Methicillin-resistant Staphylococcus aureus sterile-site infection: the importance of appropriate initial antimicrobial treatment. Crit Care Med 2006, 34:2069-2074.
41. Micek S.T., Welch E.C., Khan J., et al. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: retrospective analysis. Antimicrob Agents Chemother 2010, 54:1742-1748.
42. Kumar A., Ellis P., Arabi Y., et al. Initiation of inappropriate antimicrobial therapy results in a five-fold reduction of survival in human septic shock. Chest 2009, 135:1237-1248.
43. Ibrahim E.H., Ward S., Sherman G., et al. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001, 29:1109-1115.
44. Kollef M.H., Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998, 113:412-420.
45. Luna C.M., Vujacich P., Niederman M.S., et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997, 111:676-685.
46. Rello J., Gallego M., Mariscal D., et al. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997, 156:196-200.
47. Niederman M.S., Mandell L.A., Anzueto A., et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001, 163:1730-1754.
48. Zilberberg M.D., Shorr A.F., Micek S.T., et al. Antimicrobial therapy escalation and hospital mortality among patients with healthcare-associated pneumonia: a single-center experience. Chest 2008, 134:963-968.
49. Houck P.M., Bratzler D.W., Nsa W., et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004, 164:637-644.
50. Iregui M., Ward S., Sherman G., et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associate pneumonia. Chest 2002, 122:262-268.
51. Kang C.I., Kim S.H., Kim H.B., et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003, 37:745-751.
52. Lodies T.P., McKinnon P.S., Swiderski L., et al. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003, 36:1418-1423.
53. Kumar A., Roberts D., Wood K.E., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34:1589-1596.
54. Niederman M.S. The importance of de-escalating antimicrobial therapy in patients with ventilator-associated pneumonia. Semin Respir Crit Care Med 2006, 27:45-50.
55. A randominzed trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med 2006, 355:2619-2630. Canadian Critical Care Trials Group.
56. Kollef M.H. Diagnosis of ventilator-associated pneumonia. N Engl J Med 2006, 355:2691-2693.
57. Hoogewerf M., Oosterheert J.J., Hak E., et al. Prognostic factors for early clinical failure in patients with severe community-acquired pneumonia. Clin Microbiol Infect 2006, 12:1097-1104.
58. Schlueter M., James C., Dominguez A., et al. Practice patterns for antibiotic de-escalation in culture-negative healthcare-associated pneumonia. Infection 2010, 38:357-362.
59. Chastre J., Wolff M., Fagon J.Y., et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized controlled trial. JAMA 2003, 290:2588-2598.
60. Schuetz P., Christ-Crain M., Thomann R., et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009, 302:1059-1066.
61. Bouadma L., Luyt C.E., Tubach F., et al. Use of procalcitonin to reduce patient's exposure to antibiotics in intensive care units (PRORATA trial): a multicenter randomized controlled trial. Lancet 2010, 375:463-474.
62. Soriano A., Marco F., Martinez J.A., et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008, 46:193-200.
63. Haque N.Z., Cahuayme Zaniga L., Peyrani P., et al. Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care- associated pneumonia. Chest 2010, 138:1356-1362.
64. Lamer C., de beco V., Soler P., et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993, 37:281-286.
65. Cruciani M., Gattr G., Lazzarini L., et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996, 38:865-869.
66. Boselli E., Breilh D., Rimmelé T., et al. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med 2005, 33:1529-1533.
67. Stevens D.L., Ma Y., Salmi D.B., et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007, 195:202-211.